Telix Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Telix Pharmaceuticals (TLX).

Price Target Range — 8 Quarters

Analyst Consensus — 5 Analysts

4Buy

1Hold

Consensus RatingBuy# Analysts5Avg. Consensus PT$21Upside to Avg. PT+89.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 25, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$20
Sep 23, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$22
Sep 15, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$20
Sep 14, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$22
Sep 2, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$20
Aug 20, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$22
Jul 7, 2026	Citigroup	Laura Sutcliffe	PT Cut	Buy	$23→$22
Jul 7, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$20
Jul 6, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$22
Apr 13, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$22
Apr 13, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$20
Apr 7, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$22
Apr 7, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$20
Feb 24, 2026	Citigroup	Laura Sutcliffe	PT Raise	Buy	$22→$23
Jan 21, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$20
Dec 22, 2025	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$20
Sep 23, 2025	UBS	David Dai	PT Cut	Buy	$23→$20
Sep 18, 2025	Citigroup	Laura Sutcliffe	Initiate	Buy	$22
Sep 10, 2025	HC Wainwright & Co.	Robert Burns	PT Cut	Buy	$23→$20
Aug 28, 2025	JP Morgan	—	Downgrade	Overweight→Neutral	—

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Buy and maintains $20 price target.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target

Wedbush analyst David Nierengarten reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Outperform and maintains $22 price target.

Benzinga Newsdesk

Telix Makes $1.65 Billion Bet on ITM to Build a Radiopharma Powerhouse

Telix Pharmaceuticals acquires ITM Isotope for $1.65B to create a radiopharmaceutical leader. Here is what investors need to know.

Vandana Singh

PRO
HC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Buy and maintains $20 price target.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target

Wedbush analyst David Nierengarten reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Outperform and maintains $22 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Buy and maintains $20 price target.

Benzinga Newsdesk

Telix Pharmaceuticals Ltd

Telix Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target

PRO
Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target

Telix Makes $1.65 Billion Bet on ITM to Build a Radiopharma Powerhouse

PRO
HC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target

PRO
Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target

People Also Watch

People Also Watch

Telix Pharmaceuticals Ltd

Telix Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target

PROWedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target

Telix Makes $1.65 Billion Bet on ITM to Build a Radiopharma Powerhouse

PROHC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target

PROWedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target

PROHC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target

PRO
Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target

PRO
Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target